Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience collecting interim data on mortality: an example from the RALES study.

Janet Wittes1, Jolie Palensky, Debra Asner

  • 1Statistics Collaborative, Inc, Washington, DC, USA. janet@statcollab.com

Current Controlled Trials in Cardiovascular Medicine
|January 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Menopausal Hormone Labels Should Rely on Evidence, Not Opinion.

JAMA·2026
Same author

Subgroups and Special Populations in Heart Failure Clinical Trials: Insights From the HFC-ARC Expert Consensus Panel.

JACC. Heart failure·2026
Same author

Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS In-Silico modelling of cardiovascular outcomes.

European journal of preventive cardiology·2025
Same author

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

The New England journal of medicine·2025
Same author

The dawn of in silico clinical trials in cardiovascular diseases: Lessons from the SIRIUS programme.

Archives of cardiovascular diseases·2025
Same author

Monitoring overall survival in pivotal trials in indolent cancers.

Statistics in biopharmaceutical research·2025

Endpoint sweeps in the Randomized Aldactone Evaluation Study (RALES) may have delayed early stopping for efficacy by inflating reported deaths. Active reporting is recommended for future clinical trials.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Cardiology

Background:

  • The Randomized Aldactone Evaluation Study (RALES) investigated spironolactone's effect on mortality in patients.
  • The study utilized semiannual Data Safety Monitoring Board (DSMB) meetings with prespecified guidelines for efficacy stopping.
  • Endpoint sweeps were conducted before DSMB meetings to confirm participant vital status.

Purpose of the Study:

  • To evaluate the impact of endpoint sweeps on interim analyses in clinical trials.
  • To assess if endpoint sweeps influenced the timing of stopping the RALES trial for efficacy.

Main Methods:

  • Computer simulation was employed to model the effect of endpoint sweeps.
  • The simulation analyzed the impact on reported deaths and the crossing of statistical boundaries.

Related Experiment Videos

Main Results:

  • Endpoint sweeps led to an estimated 5-8% increase in reported deaths at interim analyses.
  • The RALES trial crossed its efficacy boundary at the fifth interim analysis.
  • Earlier stopping might have occurred after the fourth interim analysis without sweeps, assuming prompt death reporting.

Conclusions:

  • Endpoint sweeps can artificially inflate reported events, potentially delaying trial closure for efficacy.
  • Active reporting of primary endpoints and endpoint sweeps are recommended for trials with interim analyses.
  • While sweeps present practical challenges, they are valuable for long follow-up intervals or complex endpoint adjudication.